share_log

BioVie | S-1: General form for registration of securities under the Securities Act of 1933

BioVie | S-1: General form for registration of securities under the Securities Act of 1933

BioVie | S-1：證券上市註冊聲明
美股SEC公告 ·  2024/11/22 06:34

Moomoo AI 已提取核心訊息

On November 21, 2024, BioVie filed a registration statement with the SEC to offer up to 7,711,613 shares of Class A common stock for resale by selling stockholders. These shares are issuable upon the exercise of various warrants, including Private Placement I and II Warrants, and Placement Agent Warrants I-V, issued in connection with multiple offerings throughout 2024.The company will not receive proceeds from the resale of shares by the selling stockholders. However, it will receive nominal cash from the exercise of warrants, which will be used for working capital and general corporate purposes. BioVie's common stock is traded on Nasdaq under the symbol "BIVI," with a closing price of $3.51 per share on November 19, 2024.Investors are advised to review the "Risk Factors" section in the prospectus for potential risks associated with investing in these securities. The registration is part of BioVie's strategy to satisfy registration rights granted to the selling stockholders.
On November 21, 2024, BioVie filed a registration statement with the SEC to offer up to 7,711,613 shares of Class A common stock for resale by selling stockholders. These shares are issuable upon the exercise of various warrants, including Private Placement I and II Warrants, and Placement Agent Warrants I-V, issued in connection with multiple offerings throughout 2024.The company will not receive proceeds from the resale of shares by the selling stockholders. However, it will receive nominal cash from the exercise of warrants, which will be used for working capital and general corporate purposes. BioVie's common stock is traded on Nasdaq under the symbol "BIVI," with a closing price of $3.51 per share on November 19, 2024.Investors are advised to review the "Risk Factors" section in the prospectus for potential risks associated with investing in these securities. The registration is part of BioVie's strategy to satisfy registration rights granted to the selling stockholders.
2024年11月21日，BioVie向美國證券交易委員會提交了註冊聲明，要求出售最多7,711,613股A類普通股，供出售股東轉售。這些股票可在行使各種認股權證後發行，包括與2024年全年多次發行相關的第一和第二期私募認股權證以及配售代理認股權證 I-V。該公司不會獲得出售股東轉售股票的收益。但是，它將通過行使認股權證獲得名義現金，這些現金將用於營運資金和一般公司用途。BioVie的普通股在納斯達克上市，股票代碼爲 「BIVI」，2024年11月19日的收盤價爲每股3.51美元。建議投資者查看招股說明書中的 「風險因素」 部分，了解與投資這些證券相關的潛在風險。該註冊是BioVie滿足向出售股東授予註冊權的戰略的一部分。
2024年11月21日，BioVie向美國證券交易委員會提交了註冊聲明，要求出售最多7,711,613股A類普通股，供出售股東轉售。這些股票可在行使各種認股權證後發行，包括與2024年全年多次發行相關的第一和第二期私募認股權證以及配售代理認股權證 I-V。該公司不會獲得出售股東轉售股票的收益。但是，它將通過行使認股權證獲得名義現金，這些現金將用於營運資金和一般公司用途。BioVie的普通股在納斯達克上市，股票代碼爲 「BIVI」，2024年11月19日的收盤價爲每股3.51美元。建議投資者查看招股說明書中的 「風險因素」 部分，了解與投資這些證券相關的潛在風險。該註冊是BioVie滿足向出售股東授予註冊權的戰略的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    ImmunoPrecise Antibodies
    IPA
    -- 0.697
    Nutriband
    NTRB
    -- 6.840
    Seres Therapeutics
    MCRB
    -- 0.930
    Rein Therapeutics
    RNTX
    -- 2.420
    Absci Corp
    ABSI
    -- 3.990
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。